This report summarizes clinical trials and prospective observational studies in humans, published in peer reviewed journals, that focus on medical cannabis formulations consistent with Minnesota’s Medical Cannabis Program. It also summarizes existing dosing guidelines and identifies documents and resources that may be useful to health care providers, pharmacists, patients, and their caregivers.
The body of this report contains a section for each of the qualifying medical conditions. At the beginning of each section (or subsection, in the case of cancer) there are comments providing an overview of the scientific articles that follow. Below the citation for each article is a condensed description of the study and its results.
Because cannabis is still classified as a Schedule I drug under the federal Controlled Substances Act of 1970, there are no federal guidelines for its use, or federally reviewed dosing protocols for its use. Its classification also makes it very difficult to conduct research on cannabis to determine whether it is an effective treatment for various conditions, and what the optimal dosing protocols are for various products and conditions. Most of the larger studies have occurred outside the U.S.
